Stroke

OMRON Healthcare Evolves Going for Zero Mission to Address AFib Epidemic

Retrieved on: 
Tuesday, March 26, 2024
Research, Blood pressure, American Heart Association, Exercise, Digital, Intelligence, Atrial fibrillation, Risk, Education, Patient, Knowledge, Stroke, Social media, Splenic infarction, Ageing, Diet, Behavior, Survivor, Smoking, EKG, Marketing, OMRON, Nursing

HOFFMAN ESTATES, Ill., March 26, 2024 /PRNewswire/ -- Global heart health leader OMRON Healthcare today announced an evolution of its Going for Zero mission to eliminate heart attack and stroke with increased focus on atrial fibrillation (AFib), expanded education initiatives, and advancement of its digital health transformation to support a healthcare system facing staffing shortages and crisis-level health inequities.

Key Points: 
  • OMRON Healthcare evolves Going for Zero mission to focus on AFib, education, and digital transformation.
  • "OMRON Healthcare is recognized for our Going for Zero mission to eliminate heart attack and stroke.
  • Teaching people how to change their behavior for better heart health is at the core of our Going for Zero mission," said Jill Person, executive director of marketing at OMRON Healthcare.
  • OMRON Healthcare's evolution into a digital health company will be a key factor in achieving its Going for Zero mission.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

RWJBarnabas Health and Rutgers Health to Showcase Breakthrough Cardiology Data at the American College of Cardiology Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
CMR, TME, FACC, National Health Interview Survey, Research, Obesity, Hypertension, MRI, Cooperman Barnabas Medical Center, Facial muscles, HIV, Diabetes, Risk, National Health, Patient, Stroke, RWJBarnabas Health, Community Medical Center, Mortality, Aortic stenosis, American College of Cardiology, Telehealth, Faculty, New Jersey Medical School, NHIS, Abstract, American College, Smoking, LVDD, Rutgers University, Division, TAVR, Collection, Jersey City Medical Center, ACC, YPLL, Acute coronary syndrome, Health, Meta-analysis, Dietary supplement

WEST ORANGE, N.J., March 25, 2024 /PRNewswire/ -- Physician-scientists from RWJBarnabas Health and Rutgers Health will present an extensive portfolio of innovative cardiovascular data from their clinical research program at the American College of Cardiology's (ACC) Annual Scientific Session & Expo in Atlanta, Georgia on April 6 to 8, 2024. A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.

Key Points: 
  • A total of 59 abstracts have been accepted, composed of data evaluating and educating on risk factors, treatment options and ongoing research advances to improve cardiovascular care and outcomes for patients.
  • RWJBarnabas Health cardiac centers of excellence are nationally recognized for patient care and superior outcomes, including being named as one of Becker's top 100 Great Heart Programs in the country and recognized by American College of Cardiology as a Proven Quality Program.
  • Prior studies suggest that distinct patient subgroups with aortic stenosis may experience left ventricular systolic and diastolic dysfunction before the development of severe AS.
  • The study included patients who had received an angiogram done within 14 days of the CMR.

Bone Health and Osteoporosis Foundation Applauds President's Executive Order Directing Bold Action to Improve Care for Those With Osteoporosis

Retrieved on: 
Thursday, March 21, 2024
Milliman, Bone fracture, Bone health, First lady, Osteoporosis, White, Patient, Nursing, Fracture, Executive order, Research, HHS, Policy, Splenic infarction, Ageing, Laboratory, Stroke, Woman, Breast cancer, Medicare, Government, Federation, Dietary supplement

ARLINGTON, Va., March 21, 2024 /PRNewswire/ -- Earlier this week, President Biden issued a sweeping Executive Order directing Federal government agencies to take bold actions to improve women's health research and to assure that the "gains made in research laboratories are translated into real-world clinical benefits for women." In his published statement accompanying the Executive Order, the President specifically highlighted osteoporosis as a critical women's health condition that was being targeted for action. 

Key Points: 
  • In his published statement accompanying the Executive Order , the President specifically highlighted osteoporosis as a critical women's health condition that was being targeted for action.
  • Specifically, the White House statement says that the President is directing the Department of Health and Human Services (HHS) to "identify ways to improve … the clinical care that women receive" for diseases and conditions such as osteoporosis.
  • "This is a major victory for the 10 million Americans with osteoporosis," said Claire Gill, CEO of the Bone Health and Osteoporosis Foundation.
  • "We're grateful to President Biden and the First Lady for recognizing the need for action to help those with osteoporosis.

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Retrieved on: 
Thursday, March 21, 2024
Discovery, Research, Depression, Epilepsy, MIRA, Development, Shire (pharmaceutical company), Stroke, Litoxetine, IND, VPA, Sanofi, Clinical trial, Research and development, Investigational New Drug, Drug development, Marketing, Pharmaceutical industry

MIAMI, March 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor.

Key Points: 
  • Dr. Angel brings over 40 years of preclinical, clinical and regulatory acumen to MIRA.
  • He has significantly contributed to the research, development and regulatory approval of groundbreaking medications over his remarkable career.
  • Additionally, his activities contributed to the development and marketing of Mizollen (mizolastine), Xatral (alfuzosin) and Ambien (zolpidem).
  • "We are truly honored to have Dr. Angel on our team," stated Erez Aminov, Chairman & CEO of MIRA.

Stamford Health and Columbia University Irving Medical Center Deepen Relationship With Neurosciences Partnership

Retrieved on: 
Thursday, March 21, 2024
Stroke, American Heart Association, Brain, Neuroscience, Joint Commission, Partnership, Stamford Hospital, Headache, Patient, Research, Columbia, Columbia University, Surgeon, Spine, Joint, CUIMC, Pain management, Thrombectomy, FACS, Physician, Hospital

The neurosciences partnership builds on Stamford Health's existing relationship with CUIMC and earlier this year, Stamford Health welcomed Columbia University Irving Medical Center endovascular neurosurgeon, Max Shutran, MD , to its medical staff.

Key Points: 
  • The neurosciences partnership builds on Stamford Health's existing relationship with CUIMC and earlier this year, Stamford Health welcomed Columbia University Irving Medical Center endovascular neurosurgeon, Max Shutran, MD , to its medical staff.
  • Through its expanded partnership with Columbia University Irving Medical Center, one of the nation's premier medical centers, Stamford Health provides the most advanced and sophisticated cardiac and neurosurgical care to lower Fairfield County.
  • "We are so excited for Dr. Max Shutran to join our department in this exciting new role with Stamford Health," noted E. Sander Connolly, MD , Neurosurgeon-in-Chief at Columbia University Irving Medical Center.
  • "Our partnership with Columbia University Irving Medical Center is one that we are extremely proud of," added Rod Acosta, MD, Chief Physician Executive and President & CEO of Stamford Health Medical Group.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
Wednesday, March 20, 2024
Palpitations, Varenicline, Chest pain, Xerostomia, Dizziness, Weakness, Caregiver, Nervous, Indigestion, Sleep, Risk, Headache, NPN, Health, Nicotine, Angina, Internet, Stroke, Constipation, Smoke, Death, Heartburn, Health Canada, Arrhythmia, Nausea, Medicine, Nursing, Safety, Fatigue, Vomiting, Blurred vision, Allergy, Parent, Chronic pain, Advertising, Tobacco

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

CHOP Researchers Find Branched Chain Amino Acid Supplementation May Aid in Concussion Recovery

Retrieved on: 
Tuesday, March 19, 2024
Online, Research, Mind, Stroke, Concussion, Assistant, CHOP, Critical Care Medicine (journal), Patient, DSM-IV codes, Journal, Anesthesiology, Leucine, Dana Foundation, Health, University, Doctor of Philosophy, MD, Human, Valine, Critical care, Adolescence, Isoleucine, Veteran, Clinical trial, BCAA, Pediatrics, Traumatic brain injury, National Institutes of Health, Hospital, Head injury, Randomized controlled trial, Safety, Ageing, HIT, Bangladesh Technical Education Board, Medicine, Children's Hospital of Philadelphia, MSCE, Dietary supplement

PHILADELPHIA, March 19, 2024 /PRNewswire/ -- In the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in pediatric patients, scientists from the Minds Matter Concussion Frontier Program at Children's Hospital of Philadelphia (CHOP) have found preliminary evidence that adolescents and young adults with concussion who take a specific formulation of branched chain amino acid (BCAA) supplements after injury experience faster symptom reduction and return to physical activity. The findings were published online by the Journal of Neurotrauma.

Key Points: 
  • The mainstay of treatment remains symptom management with temporary modification of cognitive and physical activity and over the counter medication.
  • Although active rehabilitation strategies have shown promise for improving recovery time, including aerobic, vestibular, and vision interventions, these can be time and labor intensive.
  • To date, no targeted pharmacologic intervention to improve clinical outcomes in concussion has been evaluated in humans.
  • However, prior to this study, no human studies involving adolescents and young adults have assessed the potential benefits of this formulation of BCAAs as a specific treatment to aid in concussion recovery.

Everest Rehabilitation Hospitals Announces Plans to Construct a 40-Bed Physical Rehabilitation Hospital in McKinney, Texas (their 16th location and 2nd in DFW).

Retrieved on: 
Tuesday, March 19, 2024
Central Expressway, Environment, Television, Patient, SNF, Dallas–Fort Worth metroplex, Brain, Stroke, Hospital, Trauma, Rehabilitation, Quality of life, City, Amputation, Physician, Health

DALLAS and MCKINNEY, Texas, March 19, 2024 /PRNewswire-PRWeb/ -- Today, Everest Rehabilitation Hospitals announced plans to construct a 40-bed inpatient physical rehabilitation hospital in McKinney, Texas. This will be Everest's second location in the DFW Metroplex.

Key Points: 
  • Everest announces McKinney, TX as its latest location for another modern comprehensive physical rehabilitation hospital.
  • DALLAS and MCKINNEY, Texas, March 19, 2024 /PRNewswire-PRWeb/ -- Today, Everest Rehabilitation Hospitals announced plans to construct a 40-bed inpatient physical rehabilitation hospital in McKinney, Texas.
  • We are thrilled to serve Collin County and the surrounding communities by providing the absolute best physical rehabilitation solution.
  • This newest location will feature Everest's new, two-story, 40-bed physical rehabilitation hospital solution to accommodate ideal locations with smaller site availability in the rapidly growing community of McKinney, Texas.